This is an internal meeting for the HD-CAB Team members.

Prof Bernhard Landwehrmeyer will talk about where in the clincial trial process patient input is of most importance and relevance.

Maria Mavris will be presenting the next training session.  She works for the European Medicines Agency and has a wealth of experience with rare disease drug development and patient relations.  She will explain what’s involved in granting marketing authorization in Europe and how the agency gets patients involved.  Although Maria’s focus will be on Europe, she will also touch on the US (FDA) process so it will be valuable learning for all of us, given that most countries look to either the EMA or FDA when they consider marketing authorization. This is an internal training for Team Members